Article Information
- Received November 8, 2017
- Revision received December 23, 2017
- Accepted January 18, 2018
- First published February 26, 2018.
- Version of record published April 11, 2018.
Author Information
Author contributions
Author contributions: L.M.S. and R.M. designed research; L.M.S., S.A., and J.R.G.-M. performed research; L.M.S. analyzed data; L.M.S. and R.M. wrote the paper.
Disclosures
- Received November 8, 2017.
- Revision received December 23, 2017.
- Accepted January 18, 2018.
This work was supported by grants from the Spanish Ministries of Economía, Industria y Competitividad (SAF2016-78207-R and PCIN-2015-098) and of Sanidad Servicios Sociales e Igualdad, Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas [CIBERNED] (CB06/05/0055, PNSD2016I033), the Ramón Areces Foundation (172275), and from Secretaría de Ciencia, Tecnología e Innovacíon [SECITI] from Ciudad de Mexico (037/2016) to R.M., J.R.G.-M. received scholarships from Consejo Nacional de Ciencia y Tecnología and SECITI of Ciudad de México. L.M.S., S.A., and R.M. were awarded the First Prize and Special Prize at the XV Archimedes University Competition from the Spanish Ministry of Educación Cultura y Deporte and ONCE Foundation. We thank Beatriz Pro and Emilia Rubio for technical assistance and Dr. J. DeFelipe for providing the Lucifer yellow antibody.
The authors declare no competing financial interests.
- Corresponding should be addressed to Dr. Rosario Moratalla, Cajal Institute (CSIC), Avenida Dr. Arce 37, 28002 Madrid, Spain. moratalla{at}cajal.csic.es
Other Version
- previous version (February 26, 2018).
- You are viewing the most recent version of this article.
Online Impact